REGENXBIO
NEWS
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter’s lead program, AMT-260, an advanced treatment for TLE.
The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
Under the terms of the deal, RegenxBio granted Pfizer a non-exclusive global license, with rights to sublicense, RegenxBio’s NAV AAV9 vector. In return, Pfizer is paying RegenxBio an upfront payment, various milestones and royalties on net sales.
Maryland-based REGENXBIO is expanding its gene therapy pipeline to include a new treatment for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease.
Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.
Gene therapy treatment is a high risk, high reward venture, but the promises of a therapy developed through these programs could be life-changing for patients.
JOBS
IN THE PRESS